Multi-Omics Integration: Fusing Biological Data Layers

Under scientific review

This page describes computational methods for integrating high-dimensional biological data. Use it for orientation, not clinical decision-making.

No single biological layer holds the complete picture of cancer. A DNA mutation (Genomics) may be silenced by DNA methylation (Epigenomics), transcribed into RNA (Transcriptomics) but degraded before translation into functional protein (Proteomics), or offset by altered metabolite fluxes (Metabolomics).

Multi-Omics Integration combines these heterogeneous high-dimensional layers to discover disease subtypes, uncover driver pathways, and identify predictive biomarkers. For software engineers, multi-omics integration is an multimodal data fusion problem across datasets with vastly different scales, noise profiles, and missingness structures.

---

1. Fusion Strategies in Machine Learning

How layers are combined dictates model capacity, interpretability, and vulnerability to overfitting:

Early Fusion:        [ Genomics ] + [ Transcriptomics ] + [ Proteomics ] ──► [ Concatenated Matrix ] ──► [ Model ]
Intermediate Fusion: [ Layer 1 ] ──┐
                     [ Layer 2 ] ──┼──► [ Shared Latent Space (e.g. MOFA) ] ──► [ Downstream Task ]
                     [ Layer 3 ] ──┘
Late Fusion:         [ Model 1 ] ──┐
                     [ Model 2 ] ──┼──► [ Ensemble / Stacking Classifier ] ──► [ Prediction ]
                     [ Model 3 ] ──┘

A. Early Fusion (Concatenation)

• Concept: Flattening and concatenating all omics matrices ($N \times P_1, N \times P_2, \dots$) into one wide matrix before feature selection.
• Drawback: Dominated by high-feature-count modalities (e.g., RNA-seq with 20,000 genes vs. clinical data with 10 features). Vulnerable to scale mismatch and missing modalities.

B. Intermediate Fusion (Joint Latent Representation) — The Gold Standard

• Concept: Learns a lower-dimensional shared factor space that captures co-variance across modalities while preserving modality-specific variation.
• Key Methods:
  • MOFA / MOFA+ (Multi-Omics Factor Analysis): Bayesian factor analysis model that decomposes multi-omics matrices into shared factors.
  • iClusterPlus: Joint latent variable model for clustering subtype discovery.
  • Graph Neural Networks (GNNs): Constructing heterogeneous graphs where nodes are genes, proteins, drugs, and patients, and edges represent biological interactions.

C. Late Fusion (Ensemble / Decision Stacking)

• Concept: Training separate models on each omics layer independently, then combining their prediction probabilities (via weighted averaging or a meta-learner).
• Advantage: Modular, robust to missing modalities for a given patient, and easy to audit layer-specific contributions.

---

2. Technical & Mathematical Challenges

1. The Curse of Dimensionality ($P \gg N$): A typical study might have $N = 500$ patients but $P = 100,000+$ total features across DNA, RNA, and protein layers. Regularization (Lasso/ElasticNet), dimensionality reduction, and strict cross-validation are essential to prevent fitting to noise.
2. Data Missingness: Not all patients undergo all assays. Algorithms must handle structured missingness without discarding partially profiled cohorts.
3. Batch Effects & Platform Heterogeneity: Data generated across different sequencing centers or batch runs carry technical noise. Tools like ComBat or limma::removeBatchEffect must be applied before fusion.

---

3. Benchmark Public Datasets for Multi-Omics

• TCGA (The Cancer Genome Atlas): Over 11,000 patients across 33 cancer types with matched WES, RNA-seq, miRNA, methylation, RPPA (proteomics), and clinical data. Accessible via cBioPortal or the NCI Genomic Data Commons (GDC).
• CPTAC (Clinical Proteomic Tumor Analysis Consortium): The premier proteogenomic dataset, pairing deep mass-spectrometry proteomics/phosphoproteomics with DNA/RNA sequencing.

---

References

1. Argelaguet, R., et al. (2018). Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Molecular Systems Biology, 14(6), e8124.
2. Shen, R., et al. (2009). Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtyping. Bioinformatics, 25(22), 2906-2912.
3. Hoadley, K. A., et al. (2018). Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 173(2), 291-304.